Products

Niacin (nicotinic acid) semonotherapy inogona kuderedza njodzi yechirwere chevascular, asi maitiro ayo echiito anoramba achikakavadzana, uye anogona kunge asina kutsamira pane systemic lipid inogadzirisa mhedzisiro.Niacin ichangobva kuratidzwa kuvandudza endothelial basa uye vascular regeneration, yakasununguka pakugadzirisa dyslipidemia, mumakonzo emhando dzekukuvara kwevascular uye chirwere chemetabolism.Sezvinogoneka biosynthetic precursor yeNAD(+), niacin inogona kuunza izvi vascular mabhenefiti kuburikidza neNAD(+)-inotsamira, sirtuin (SIRT) yakapindirana mhinduro.Neimwe nzira, niacin inogona kuita kuburikidza neyayo receptor, GPR109A, kukurudzira endothelial basa, kunyange endothelial masero asingazivikanwe kuratidza iyi receptor.Takafungidzira kuti niacin inonatsiridza endothelial cell function panguva yekusangana kune lipotoxic mamiriro uye takatsvaga kuona iyo inogona kuita nzira (s) inobatanidzwa.Angiogenic basa mune yakawandisa palmitate yakaongororwa nekuumbwa kwechubhu zvichitevera kurapwa kwema cell endothelial emunhu (HMVE C) aine chero yakaderera yakaderera yeacin (10 μM), kana nicotinamide mononucleotide (NMN) (1 μM), yakananga NAD (+) precursor.Kunyangwe zvese zviri zviviri niacin neNMN zvakavandudza HMVEC chubhu kuumbwa panguva yepalmitate kuwandisa, chete NMN yakawedzera cellular NAD (+) uye SIRT1 chiitiko.Isu takaona zvakare kuti HMVEC inotaura GRP109A.Kuita kweiyi receptor ine acifran kana MK-1903 yakadzokorodza niacin-induced kuvandudzwa muHMVEC tube formation, nepo GPR109A siRNA yakaderedza mhedzisiro ye niacin. +) biosynthesis uye SIRT1 activation, asi zviri nani kuburikidza neacin receptor activation.